These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33518029)

  • 1. Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes.
    Shao H; Laxy M; Gregg EW; Albright A; Zhang P
    Value Health; 2021 Feb; 24(2):227-235. PubMed ID: 33518029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Laiteerapong N; Cooper JM; Skandari MR; Clarke PM; Winn AN; Naylor RN; Huang ES
    Ann Intern Med; 2018 Feb; 168(3):170-178. PubMed ID: 29230472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT; Thompson MF; Sauriol L
    Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A; Rastogi M; Dhankhar P; Bell KF
    J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Diabetes Complications on HbA
    Shao H; Lin J; Zhuo X; Rolka DB; Gregg EW; Zhang P
    Diabetes Care; 2019 Nov; 42(11):2136-2142. PubMed ID: 31530661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
    Beale S; Bagust A; Shearer AT; Martin A; Hulme L
    Pharmacoeconomics; 2006; 24 Suppl 1():21-34. PubMed ID: 16800160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.
    Vijan S; Hofer TP; Hayward RA
    JAMA; 2000 Feb; 283(7):889-96. PubMed ID: 10685713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
    Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
    J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
    Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
    Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
    Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Type 2 Diabetes Microsimulation Model to Estimate Long-Term Health Outcomes, Costs, and Cost-Effectiveness.
    Hoerger TJ; Hilscher R; Neuwahl S; Kaufmann MB; Shao H; Laxy M; Cheng YJ; Benoit S; Chen H; Anderson A; Craven T; Yang W; Cintina I; Staimez L; Zhang P;
    Value Health; 2023 Sep; 26(9):1372-1380. PubMed ID: 37236396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
    Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL; Sauriol L; Minshall ME
    Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.